Pfizer
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.
Business & Industry
- New long-term data confirm Roche’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan
- Pfizer announces extension of Zithromax® Antibiotic Donation Program through 2025 to help eliminate world's leading infectious cause of blindness
- Update on Phase III clinical trials of lanabecestat for Alzheimer's disease
- Amgen, Oklahoma Health Care Authority and University of Oklahoma's Pharmacy Management Consultants partner to improve medicaid outcomes
- FDA grants Priority Review to Roche’s Hemlibra for people with haemophilia A without factor VIII inhibitors
Research & Development
- Online information on vaccines and autism not always reliable, study shows
- Researchers find link between allergen in red meat and heart disease
- Big data identifies lipids as signatures of health and disease
- University of Tokyo's RCAST, Fujitsu, and Kowa successfully create promising new compounds to fight drug-resistant cancer
- David vs Goliath: How a small molecule can defeat asthma attacks
- How to slow down Ebola
- International agreement that human-relevant research is needed to enhance drug discovery
Conferences & Events
- Ophthalmic Drugs Conference 2018
- SMi presents the launch of Cell & Gene Therapy 2018
- SMi presents the 9th Conference on Biosimilars & Biobetters
- SMi presents the 13th Conference on ADMET
- SMi presents the 2nd annual conference on Pharmaceutical Microbiology West Coast
- Introducing SMi's 6th annual conference on Pharmaceutical Freeze Drying Technology this June 2018
- Adaptive Designs in Clinical Trials Conference 2018
Regulatory Affairs
- FDA takes action against 53 websites marketing unapproved opioids as part of a comprehensive effort to target illegal online sales
- FDA approves first biosimilar to Neulasta to help reduce the risk of infection during cancer treatment
- FDA takes new steps to advance digital health, opening docket to solicit feedback on software products
- FDA approves novel preventive treatment for migraine
- FDA approves first epoetin alfa biosimilar for the treatment of anemia
- FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients
- FDA approves first therapy for rare inherited form of rickets, x-linked hypophosphatemia